In terms of novel agents and pathways, there are a number of ongoing clinical trials for JAK inhibitors—particularly JAK2 inhibitors—in advanced prostate cancer, but thus far these have not demonstrated sufficient monotherapy activity in men with mCRPC [(Beinhoff et al., 2021) and see NCT00638378; closed due to lack of efficacy]. Here, JAK2 is linked to Familial prostate cancer.